The FDA announced approval of a new RSV mRNA vaccine on October 23, 2024. This vaccine was developed and tested in a collaborative effort between ModernaTX and Merck and is intended for administration to adults 60 years of age or older. The press release announcing the approval may be found here, and manufacturer information from ModernaTX may be found here. mResvia is currently produced and distributed by ModernaTX and is available now for distribution.
The development process for this vaccine made use of Expi293F cells, a trade name variation of HEK-293 aborted fetal cells. The use of Expi293F cells was instrumental in validation of the mRNA design. Expi193F cells were transfected with the mRNA corresponding to several RSV proteins and the expression of the antigens was measured after incubation and staining. The process is described in detail in this paper, published in the journal NPJ Vaccines on February 14, 2020.
The use of Expi293F cells was essential to the development of this vaccine, therefore it is ethically compromised.
No way I’ll take this..I shall this article onto my friend here in Australia